Elan Corporation

After many attempts and failures to bring a disease-modifying therapy forward for Alzheimer’s disease, the triumph of Eisai Co., Ltd. / Biogen, Inc. ’s amyloid protofibril-clearing antibody lecanemab

An Almost Convincing Drug Castoff In 2006 I was almost convinced that the small biotech company Adherex Technologies, Inc. might do a better job with the drug eniluracil than GlaxoSmithKline plc (GS

As portfolio managers and analysts headed off to Thanksgiving family reunions, this year accompanied by clutches of lateral flow tests, the news flow in life sciences was expected to dwindle. On the W

The advisory committee review of aducanumab in November was a bruising affair for the US Food and Drug Administration, with a near unanimous vote against the drug and several pointed remarks directed